What happened
Chong Kun Dang Pharmaceutical filed provisional (unaudited) separate results for Q1 2026: revenue of US$301M (+12.2% year on year), operating profit of US$11.8M (+36.9% year on year) and net income of US$10M (+6.3% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$301M |
|---|---|
| Revenue vs a year earlier | +12.2% |
| Operating profit | US$11.8M |
| Net income | US$10M |
| Period | Q1 2026 (separate) |
| Filed | 2026-04-29, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260429800623 → open original filing |
Source: DART. Information only, not investment advice.